Background Data regarding symptoms in the lactating mother-infant dyad and their immune response to COVID-19 mRNA vaccination during lactation are needed to inform vaccination guidelines. Methods From a prospective cohort of 50 lactating individuals who received mRNA-based vaccines for COVID-19 (mRNA-1273 and BNT162b2), blood and milk samples were collected prior to first vaccination dose, immediately prior to 2nd dose, and 4-10 weeks after 2nd dose. Symptoms in mother and infant were assessed by detailed questionnaires. Anti-SARS-CoV-2 antibody levels in blood and milk were measured by Pylon 3D automated immunoassay and ELISA. In addition, vaccine-related PEGylated proteins in milk were measured by ELISA. Blood samples were collected from a subset of infants whose mothers received the vaccine during lactation (4-15 weeks after mothers’ 2nd dose). Results No severe maternal or infant adverse events were reported in this cohort. Two mothers and two infants were diagnosed with COVID-19 during the study period before achieving full immune response. PEGylated proteins were not found at significant levels in milk after vaccination. After vaccination, levels of anti-SARS-CoV-2 IgG and IgM significantly increased in maternal plasma and there was significant transfer of anti-SARS-CoV-2-Receptor Binding Domain (anti-RBD) IgA and IgG antibodies to milk. Milk IgA levels after the 2nd dose were negatively associated with infant age. Anti-SARS-CoV-2 IgG antibodies were not detected in the plasma of infants whose mothers were vaccinated during lactation. Conclusions COVID-19 mRNA vaccines generate robust immune responses in plasma and milk of lactating individuals without severe adverse events reported.
【저자키워드】 COVID-19, antibodies, SARS-CoV-2, Breastfeeding, mRNA vaccine, lactation, human milk, passive immunity, 【초록키워드】 IgM, immune response, vaccination, antibody, mRNA-1273, lactation, Symptom, ELISA, mRNA vaccines, Infant, BNT162b2, immunoassay, Infants, Cohort, IgG antibody, anti-SARS-CoV-2 antibody, IgG antibodies, anti-SARS-CoV-2 IgG, IgA, mRNA, anti-SARS-CoV-2 IgG antibodies, immune responses, adverse event, plasma, age, automated, prospective cohort, Blood, mother, dose, anti-RBD, COVID-19 mRNA vaccine, COVID-19 mRNA Vaccination, Questionnaires, Blood samples, individual, study period, blood sample, transfer, milk, maternal plasma, mRNA-based vaccines, PEGylated proteins, severe adverse events, first vaccination, significant level, mRNA-based vaccine, robust, significantly increased, Result, collected, reported, addition, generate, the vaccine, subset, were measured, IgA level, diagnosed with COVID-19, lactating, PEGylated protein, Pylon 3D, severe adverse event, were assessed, 【제목키워드】 assessment, Adverse, dyad,